

# Chronic phase Philadelphia positive CML



This flowchart can be used to determine when a patient is required to demonstrate a major cytogenetic response to treatment with PBS-subsidised imatinib mesylate (Glivec). It also indicates which reports must be supplied to Medicare Australia for continuing approval.

